The company continues to rank #1 in DMFs Available for Reference
ChemWerth, Inc., is pleased to announce that since the inception of Generic Drug User Fee Amendments (GDUFA) in 2012, the company has filed its 50th Drug Master File that the FDA has deemed as Available for Reference. The company continues to rank #1 in DMFs Available for Reference among all other peer active pharmaceutical ingredient companies.
“Contrary to an industry trend which has seen many competitors decrease their API development, we have stepped on the accelerator. We will continue to invest in specialty generic API products to support our customers around the globe, and we are committed to our vision of One World, One Quality generic APIs,” said Peter J. Werth, President and CEO, ChemWerth, Inc.
In addition to filing its 50th DMF available for reference, the company has 45 first to file APIs. Werth added, “Our customers have come to rely on ChemWerth to provide them with first to market advantage. This provides our customers with a big competitive edge and that continues to be a big reason for our success.”
